Kite Pharmaceuticals Inc. shares jumped in the extended session Monday after the biotech drug developer said a clinical study of its lead cancer drug met its primary goal. Kite shares, which had been briefly halted, surged 13% to $62.20 after hours. The company reported a mid-stage clinical study of its drug KTE-C19 showed that 76% of patients with Non-Hodgkin Lymphoma, or cancer of a part of the body’s immune system called lymphocytes, responded to the treatment, while 47% showed a complete remission.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News